Adult Solid NeoplasmPhase 1NCT00878163
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
A Phase 1 study testing Diagnostic Laboratory Biomarker Analysis, Erlotinib Hydrochloride and Gemcitabine Hydrochloride in people with Adult Solid Neoplasm and Pancreatic Acinar Cell Carcinoma, run by National Cancer Institute (NCI) at 4 sites in United States.
Trial summary
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with GDC-0449 with or without gemcitabine hydrochloride in treating patients with metastatic pancreatic cancer or solid tumors that cannot be removed by surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
- What is being tested?
- Diagnostic Laboratory Biomarker Analysis, Erlotinib Hydrochloride and Gemcitabine Hydrochloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 4 sitesUnited States
- Study dates
- 31 Mar 2009to 6 Mar 2027
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologic proof of a solid tumor that is now unresectable, not amenable to any other standard therapies, or patient refuses standard therapy
- Metastatic adenocarcinoma of the pancreas amenable to biopsies (cohort II MTD only)
- Absolute neutrophil count (ANC) >= 1,500/μL
- Platelets >= 100,000/μL
- Total bilirubin =< upper limit of normal (ULN)
- Aspartate aminotransferase (AST) =< 3 times upper limit of normal (ULN)
Show all 37Show fewer
- Creatinine =< 1.5 times ULN
- Hemoglobin >= 9.0 g/dL
- International Normalized Ratio (INR) within normal limits (for patients treated at the MTD)
- Ability to provide informed consent
- Willingness to return to Mayo Clinic for follow up
- Life expectancy >= 12 weeks
- Willingness to provide the biologic specimens as required by the protocol
- Negative serum pregnancy test done =< 7 days prior to registration
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
- Able to swallow or have medication administered through a G-tube and absorb the medication
- Participant agrees to use an acceptable form of contraception; acceptable forms of contraception:
- Latex condom (always used with spermicide)
- Diaphragm (always used with spermicide)
- Cervical cap (always used with spermicide)
- Acceptable forms of secondary contraceptions, when used along with a barrier method:
- Hormonal contraception methods, including pills, patches, rings, or injections except progestin-only containing pills (i.e. "Mini-pill")
- Tubal ligation
- Partner's vasectomy
- Intrauterine device (IUD) (non-progesterone T)
- Vaginal sponge (containing spermicide)
- 100% commitment to abstinence
- Unacceptable forms of contraception for women of childbearing potential:
- Oral contraception containing progestins only
- IUD progesterone T
- Female condom
- Natural family planning (rhythm method) or breastfeeding
- Fertility awareness
- Withdrawal
- Cervical shield
- Willing to abstain from smoking
- Willing to complete a daily pill diary
Who cannot join
- Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Any of the following prior therapies:
- Chemotherapy =< 4 weeks prior to registration
- Mitomycin C/nitrosoureas =< 6 weeks prior to registration
- Immunotherapy =< 4 weeks prior to registration
Show all 25Show fewer
- Biologic therapy =< 4 weeks prior to registration
- Radiation therapy =< 4 weeks prior to registration
- Radiation to > 25% of bone marrow
- Failure to fully recover from acute, reversible effects of prior therapy regardless of interval since last treatment
- New York Heart Association classification III or IV
- Seizure disorder
- Central nervous system (CNS) metastases if not stable for at least 2-3 months based on imaging, clinical assessment, and use of steroids, or seizure disorder
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception until 12 months after last study drug dose
- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)
- Current therapy with a CYP3A4 inhibitor or inducer
- Immunocompromised patients (other than that related to the use of corticosteroids) including patients receiving highly active antiretroviral therapy (HAART) treatment
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- Active other malignancy, excepting non-melanotic skin cancer or carcinoma-in-situ of the cervix; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
- History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
- Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjogren's syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test)
- More than 2 prior chemotherapy regimens for the current metastatic malignancy; full dose chemotherapy used in conjunction with concurrent radiation therapy will be included as prior therapy; Note: prior hormonal therapy (e.g. leuprolide, aromatase inhibitors, tamoxifen) will be allowed and not included as a prior chemotherapy
- Previous therapy with a hedgehog inhibitor
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
Orlando Health Cancer Institute
Orlando, Florida, 32806
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
About this study
Official title: Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with GDC-0449 with or without gemcitabine hydrochloride in treating patients with metastatic pancreatic cancer or solid tumors that cannot be removed by surgery. Drugs used in chemotherapy, such as GDC-0449 and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving GDC-0449 together with erlotinib hydrochloride with or without gemcitabine hydrochloride may kill more tumor cells.
Read the detailed description
PRIMARY OBJECTIVES:
- To determine the maximum tolerated dose of erlotinib hydrochloride and Hedgehog antagonist GDC-0449 with or without gemcitabine hydrochloride in patients with unresectable solid tumors.
SECONDARY OBJECTIVES:
- To describe the adverse events profile associated with these treatment regimens.
II. To describe the responses in patients treated with these regimens. III. To assess the effect of erlotinib hydrochloride and Hedgehog antagonist GDC-0449 on selected biomarkers in circulating tumor cells and tumor biopsy samples from patients with metastatic pancreatic cancer.
IV. To assess the effect of erlotinib hydrochloride and Hedgehog antagonist GDC-0449 on fludeoxyglucose F 18 positron emission tomography imaging in patients with metastatic pancreatic cancer.
- To study the association between clinical (toxicity and/or tumor response or activity) and biologic (pharmacodynamic) results associated with erlotinib hydrochloride and Hedgehog antagonist GDC-0449 in patients with metastatic pancreatic cancer.
OUTLINE: This is a dose-escalation study of erlotinib hydrochloride.
Patients receive Hedgehog antagonist GDC-0449 orally (PO) once daily (QD) and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients treated at the maximum tolerated dose undergo fludeoxyglucose F 18 positron emission tomography at baseline and on day 28. These patients also undergo tumor tissue and blood sample collection at baseline and periodically during study for correlative laboratory studies. Samples are analyzed for tyrosine phosphorylated or total MAP-K, EGFR, AKT, and other potential biomarkers of activity/response and for levels of genes transcriptionally activated (e.g., BCL-2, GLI, BFL-1/A1, 4-1BB, PTC1) by immunofluorescence, IHC, and quantitative-PCR.
After completion of study therapy, patients are followed at 3 months.
- Conditions
- Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Being tested
- Diagnostic Laboratory Biomarker Analysis, Erlotinib Hydrochloride, Gemcitabine Hydrochloride, Vismodegib
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic Laboratory Biomarker AnalysisOther
Correlative studies
Erlotinib HydrochlorideDrug
Also called CP 358, CP-358, Cp-358,774, CP358
Given PO
Also called dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar
Given IV
VismodegibDrug
Also called Erivedge, GDC 0449, GDC-0449, GDC0449
Given PO
| Study group | Role | What they receive |
|---|---|---|
| Treatment (vismodegib, erlotinib hydrochloride, gemcitabine) | Experimental | Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Receives: Other: Diagnostic Laboratory Biomarker Analysis; Drug: Erlotinib Hydrochloride; Drug: Gemcitabine Hydrochloride; Drug: Vismodegib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum tolerated dose of erlotinib hydrochloride defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients
DLT will be defined as an adverse event, according to CTCAE version 3.0, attributed (definitely, probably, or possibly to the study treatment.
Measured: 28 days
Secondary outcomes (7)
Adverse events as assessed by NCI CTCAE v3.0
The number and severity of all adverse events (overall, and by dose-level) will be tabulated and summarized.
Measured: Up to 3 months after completion of study treatment
Toxicity, defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment, graded using the NCI CTCAE version 3.0
Measured: Up to 3 months after completion of study treatment
Response as assessed by modified RECIST criteria
Summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease.
Measured: Up to 3 months after completion of study treatment
Time until treatment related grade 3+ toxicity
Measured: Up to 3 months after completion of study treatment
Time until hematologic nadirs (WBC, ANC, platelets)
Measured: Up to 3 months after completion of study treatment
Time to progression
Measured: Up to 3 months after completion of study treatment
Time to treatment failure
Measured: From registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 months after completion of study treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2009 (estimated)
- Study start31 Mar 2009
- Primary completion22 Jan 2013
- Study completion6 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adult Solid NeoplasmStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Charles Erlichman, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00878163
- Sponsor's protocol ID
- NCI-2011-01400
- Other IDs
- NCI-2011-01400, CDR0000638302, MAYO-MC0811, MC0811, 8231, P30CA015083, P50CA102701, U01CA069912
- Status last verified
- Sep 2026
- First submitted
- 7 Apr 2009
- Last updated
- 8 Sep 2026
- Results posted
- No